Xcelience and IriSys have entered into a business alliance agreement to advance the ability to streamline access to CMC and regulatory expertise for North American pharmaceutical and biotechnology companies. “IriSys has considerable experience moving compounds from early research to Phase I/II clinical trials in addition to offering full regulatory and strategic planning services,” said Derek Hennecke, chief executive officer and president of Xcelience. “This alliance provides a unique opport...